SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Mutation S769N

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There is one clinical trial.

Clinical Trials


1 Treatment Efficacy and Malaria TRANSmission After Artemisinin Combination Therapy (TRANSACT)

Artemisinin combination therapy (ACT) with artemether lumefantrine (AL) is currently the first line treatment policy in Tanzania. AL is an efficacious drug that also has the capacity to reduce malaria transmission to mosquitoes. Nevertheless, there is concern about the development of parasite resistance against AL and there have been very few clinical trials that compared different ACT regimens. A recent clinical trial shows that the combination of dihydroartemisinin-piperaquine (DP) may be more efficacious than AL and may have a more pronounced beneficial effect on post-treatment malaria transmission. Screening for molecular markers that are related to parasite susceptibility to ACT drugs and to post-ACT treatment malaria transmission can assist in preventing the development and spread of ACT resistance. In the current study, the investigators compared AL and DP for the treatment of uncomplicated malaria. The investigators endpoints are - clinical efficacy - post-treatment gametocytaemia by molecular techniques - post-treatment malaria transmission.

NCT00868465 Uncomplicated Malaria Drug: Artemether-Lumefantrine Drug: Dihydroartemisinin-piperaquine
MeSH:Mal Malaria

This resistance was associated with SNPs at codon S769N of the ATPase6 locus of P. falciparum. --- S769N ---

Primary Outcomes

Measure: To determine the clinical efficacy of artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP) in the treatment of uncomplicated falciparum malaria in children living in north-western Tanzania and in western Kenya.

Time: during 42 day follow-up

Secondary Outcomes

Measure: To determine (sub-microscopic) gametocyte carriage after treatment with AL and DP

Time: during 42 day follow-up

Measure: To determine malaria transmission to mosquitoes after treatment with AL or DP

Time: day 7 after initiation treatment

Measure: To determine molecular markers that are predictive of reduced susceptibility of parasite strains for AL and DP

Time: day 7 after initiation treatment

Measure: To determine molecular markers that are related to gametocytaemia or malaria transmission after treatment with AL and DP

Time: during 42 day follow-up

Measure: To determine the relation between treatment success and the presence of anti-malaria antibodies

Time: during 42 day follow-up

Measure: To explore the role of cellular oxidative stress in treatment with AL and DP

Time: during 42 day follow-up

Measure: To determine the relation between transmission to mosquitoes and the presence of anti-malaria antibodies

Time: day 7 after initiation treatment


HPO Nodes